Kevzara® (sarilumab) approved by fda as first and only biologic indicated for patients with polymyalgia rheumatica

Three times more patients treated with kevzara achieved sustained remission compared to placebo in phase 3 trial
REGN Ratings Summary
REGN Quant Ranking